Copertina

Correction to “Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit/Hyperactivity Disorder”

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit /Hyperactivity Disorder
di: Shen Cheng, et al.
Pubblicazione: (2024)

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis
di: Jenny‐Hoa Nguyen, et al.
Pubblicazione: (2026)

Population Pharmacokinetics and Exposure–Response Analysis of a Fixed‐Dose Combination of Ivermectin and Albendazole in Children, Adolescents, and Adults
di: Jaime Algorta, et al.
Pubblicazione: (2024)

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children
di: Sylvie Retout, et al.
Pubblicazione: (2026)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis
di: Benjamin Rich, et al.
Pubblicazione: (2025)

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents
di: Ethan A. Poweleit, et al.
Pubblicazione: (2024)

Dual Minimal Physiologically Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites in Humans
di: Weihua Jiang, et al.
Pubblicazione: (2025)

Piperacillin Population Pharmacokinetics in Plasma and Peritoneal Fluid and Dosing Optimization in Children Undergoing Liver Transplant: An Optimome Study
di: Noémie de Cacqueray, et al.
Pubblicazione: (2026)

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants
di: Ziheng Hu, et al.
Pubblicazione: (2026)

Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model
di: Thomas K. Henthorn, et al.
Pubblicazione: (2025)

Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis
di: Xiaofei Zhou, et al.
Pubblicazione: (2025)

Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
di: Jincheng Yang, et al.
Pubblicazione: (2025)

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression
di: Xiaoyu Men, et al.
Pubblicazione: (2024)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
di: Peiying Zuo, et al.
Pubblicazione: (2024)

Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling
di: Suwasin Udomkarnjananun, et al.
Pubblicazione: (2024)

Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio
di: Aiden‐Hung P. Nguyen, et al.
Pubblicazione: (2026)

Population Pharmacokinetics of siRNA JNJ ‐73763989 in Healthy Participants and Patients With Chronic Hepatitis B
di: Tetsuro Ogawa, et al.
Pubblicazione: (2025)

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity
di: Patrick O. Hanafin, et al.
Pubblicazione: (2025)

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
di: Neha Thakre, et al.
Pubblicazione: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Pubblicazione: (2024)

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations
di: Kaio Evandro Cardoso Aguiar, et al.
Pubblicazione: (2026)

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation
di: Lukas K. van Vugt, et al.
Pubblicazione: (2025)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
di: Jatinder Kaur Mukker, et al.
Pubblicazione: (2025)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
di: Emiel Leegwater, et al.
Pubblicazione: (2024)

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV
di: Paul Thoueille, et al.
Pubblicazione: (2024)

Understanding Atomoxetine Exposure Variability in Children and Adolescents With ADHD Through Population Pharmacokinetics
di: Kevin. V. Tobin, et al.
Pubblicazione: (2026)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
di: Gerald Chun‐To So, et al.
Pubblicazione: (2025)

PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors
di: Kenichi Umehara, et al.
Pubblicazione: (2024)

A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition
di: Stef Schouwenburg, et al.
Pubblicazione: (2024)

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
di: Yuki Ujihira, et al.
Pubblicazione: (2025)

Comment on “Understanding Atomoxetine Exposure Variability in Children and Adolescents with ADHD through Population Pharmacokinetics”
di: Madhuri Tribhuvan, et al.
Pubblicazione: (2026)

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth
di: Jack W. Staples, et al.
Pubblicazione: (2026)

Best Practices for Pharmacokinetic Studies of New Chemical Entities
di: Ya‐Feng Wen, et al.
Pubblicazione: (2024)

Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
di: Annie Lumen, et al.
Pubblicazione: (2024)

Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population‐Based Cohort Study
di: Hyesung Lee, et al.
Pubblicazione: (2025)

Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
di: Olena Anoshchenko, et al.
Pubblicazione: (2024)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
di: Eugene Jeong, et al.
Pubblicazione: (2024)

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
di: Million A. Tegenge, et al.
Pubblicazione: (2025)

A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus
di: Gerald C. So, et al.
Pubblicazione: (2024)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
di: Emily Mannix, et al.
Pubblicazione: (2026)